Navigation Links
Vitamin E in front line of prostate cancer fight
Date:10/19/2010

Survival rates of the world's most common cancer might soon be increased with a new vitamin E treatment which could significantly reduce tumour regrowth.

Queensland University of Technology (QUT) prostate cancer researchers are leading the fight against a disease which kills 3000 Australian men a year.

Dr Patrick Ling, whose research will be a centrepiece of the new $354 million Translational Research Institute (TRI) when it opens in Brisbane, is leading a team of researchers who have identified a particular constituent of vitamin E, known as tocotrienol (T3), which can inhibit the growth of prostate tumours.

Construction of TRI officially began today (October 19) at the Princess Alexandra Hospital. The world-class facility brings together some of Queensland's best medical researchers from four leading Australian research facilities to turn their work into accessible and potentially life-saving health treatments.

Dr Ling's research has been funded by Davos Life Science in Singapore, who recently awarded him a further $128,000 to undertake a one-year study of the long-term effectiveness of T3 to prevent the recurrence of treated prostate cancer tumours.

"Prostate cancer is the most common type of cancer in developed countries," Dr Ling said.

"It is responsible for more male deaths than any other cancer, except lung cancer."

Dr Ling said existing chemotherapy and hormonal therapy treatment of prostate cancer was insufficient because it failed to kill off the prostate cancer stem cells (CSCs) which were believed to be responsible for the regrowth of tumours.

However, the research team have discovered a particular form of T3, called gamma-tocotrienol (γ-T3), can successfully kill off the prostate cancer CSCs.

"Currently there is no effective treatment for metastatic prostate cancer, because it grows back after conventional therapies in more than 70 per cent of cases," he said.

"But with γ-T3, QUT researchers have found a better way to treat prostate cancer, which has the potential to inhibit recurrence of the disease."

Dr Ling said in animal trials, γ-T3 completely inhibited tumour formation in more than 70 per cent of the mice implanted with prostate cancer cells and fed the vitamin E constituent in water. In the remaining cases, tumour regrowth was considerably reduced, while tumours reformed in 100 per cent of the control group.

The findings were published recently in the International Journal of Cancer.

The next stage of Dr Ling's study has begun and will determine the long-term effectiveness of the γ-T3 treatment, with plans to progress to clinical trials in the future.

"Previous clinical trials using another vitamin E constituent to inhibit prostate cancer development were unsuccessful, but these trials did not use the vitamin E constituent γ-T3," he said.

"Other research has found γ-T3 is also effective in suppressing other types of cancer, including breast, colon, liver and gastric."

Dr Ling said while not all vitamin E preparations had the active constituent, natural vitamin E obtained from palm oil was rich in γ-T3.

Professor Ross Young, from QUT's Institute of Health and Biomedical Innovation (IHBI), said one of TRI's greatest strengths was to bring together leading researchers.

"Collaboration, which combines the expertise of researchers from different disciplines and institutions to achieve common goals, will lead to better solutions," Professor Young said.

QUT Vice-Chancellor Professor Peter Coaldrake said TRI would greatly benefit Queensland's and Australia's economy and ability to attract the world's best researchers to our shores.

"By having this world-class facility producing research of the highest quality, we will be increasing Queensland's international competitiveness in research," Professor Coaldrake said.


'/>"/>

Contact: Rachael Wilson
rachael.wilson@qut.edu.au
Queensland University of Technology
Source:Eurekalert

Related biology news :

1. Dont forget the vitamin A when working with its carrier protein
2. Vitamin C supplements may reduce benefit from wide range of anti-cancer drugs
3. Vitamin D a key player in overall health of several body organs, says UC Riverside biochemist
4. Lack of vitamin D linked to Parkinsons disease
5. Vitamin K does not stem BMD decline in postmenopausal women with osteopenia
6. Optimal dose of vitamin E maximizes benefits, minimizes risk
7. Lung airway cells activate vitamin D and increase immune response
8. Could vitamin D save us from radiation?
9. Vitamin C lowers levels of inflammation biomarker considered predictor of heart disease
10. Vitamin D found to fight placental infection
11. Calcium and vitamin D may not be the only protection against bone loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
Breaking Biology News(10 mins):
(Date:4/29/2016)... Diego, CA (PRWEB) , ... April 29, 2016 , ... ... Foundation (NSCF) to support the development of a patient-specific stem cell therapy for the ... in the lab of Dr. Jeanne Loring at The Scripps Research Institute in San ...
(Date:4/28/2016)... ... April 28, 2016 , ... Connecticut Innovations ... growing companies, today announced the launch of VentureClash , a $5 million ... , “VentureClash looks to attract the best early-stage companies here in Connecticut, ...
(Date:4/27/2016)... ... ... Shimadzu Scientific Instruments (SSI) will be showcasing a broad ... Expo. Shimadzu’s high-performance instruments enable laboratories to test cannabis products for potency, moisture, ... booth 1021 to learn how Shimadzu’s instruments can help improve QA/QC testing, peak ...
(Date:4/27/2016)... ... April 27, 2016 , ... The ... announce the appointment of John Tilton as Chief Commercial Officer.  Mr. Tilton joined ... of the founding commercial leaders responsible for the commercialization of multiple orphan drug ...
Breaking Biology Technology: